Risk factor
Low price volatility
Profitability factor
Decent dividends
About
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E
Target Price
The average target price of 4114.TWO is 37.0 and suggests 34.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to